GlassScriptPhysician profile
Joseph Eric Franklin
NPI 1952869380
$3,835.28
in general payments reported to CMS, 2019-2025
31 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $748 · 2022: $1,326 · 2023: $756 · 2024: $754 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,761.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,761.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $455.42 | 2021-2023 | |
| Gilead Sciences, INC. | $445.75 | 2022-2024 | Epclusa |
| Abbvie INC. | $423.84 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $396.02 | 2021-2025 | Austedo Xr, Uzedy, Austedo |
| Otsuka America Pharmaceutical, INC. | $342.01 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Novo Nordisk INC | $246.88 | 2021-2024 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $228.38 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Neurocrine Biosciences, INC. | $213.17 | 2021-2024 | Ingrezza |
| Lundbeck LLC | $137.12 | 2021-2023 | Rexulti |
| Lilly USA, LLC | $118.38 | 2021-2023 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $83.16 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $78.61 | 2022-2023 | Hetlioz, Fanapt |
| Sientra, INC. | $78.28 | 2022 | |
| Mylan Specialty L.P. | $75.75 | 2021-2023 | Yupelri |
| Pfizer INC. | $55.31 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $51.54 | 2024-2025 | Aristada, Vivitrol, Lybalvi |
| Axsome Therapeutics, INC. | $49.78 | 2024-2025 | Auvelity |
| Astellas Pharma US INC | $44.88 | 2022-2023 | Myrbetriq |
| Glaxosmithkline, LLC. | $43.42 | 2024-2025 | Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $43.27 | 2025 | Caplyta |
| Amgen INC. | $42.75 | 2022-2024 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.54 | 2022-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $26.46 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.44 | 2021-2022 | |
| Indivior INC. | $23.48 | 2023 | Sublocade |
| Almatica Pharma LLC | $17.01 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.29 | 2025 | Invega Sustenna |
| Exact Sciences Corporation | $13.11 | 2023 | Cologuard Collection Kit |
| Corium, LLC | $12.50 | 2024 | Azstarys |
| Genentech USA, INC. | $12.00 | 2021 | |
| Organon LLC | $8.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Franklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.